General Guidelines for Experimenting with HIV

Karen B. Byers1, Alan Engelman2, Benjamin Fontes3

1 Dana Farber Cancer Institute, Boston, Massachusetts, 2 Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts, 3 Yale University, New Haven, Connecticut
Publication Name:  Current Protocols in Immunology
Unit Number:  Unit 12.1
DOI:  10.1002/0471142735.im1201s59
Online Posting Date:  May, 2004
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

Performing experiments using human immunodeficiency virus (HIV)‐infected materials represents a potential biological hazard for the investigator. An intensive training program for laboratory personnel must always precede the actual execution of research involving manipulation of HIV. In addition, appropriate sterile tissue culture techniques are absolute prerequisites for producing meaningful experiments and for achieving safe working conditions. In most circumstances more than one investigator uses the same HIV research facility; therefore, careful training in biosafety is mandatory not only for self‐protection, but for the safety of other investigators as well. The first protocol in this unit establishes a general framework for working safely with HIV and the second describes the proper storage of HIV stocks and test supernatants.

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Basic Protocol 1: General Guidelines for Working Safely with HIV
  • Basic Protocol 2: Preservation of Viral Stocks and Infected Cells
  • Commentary
  • Literature Cited
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: General Guidelines for Working Safely with HIV

  Materials
  • 70% ethanol
  • Bleach
  • Virucidal disinfectants
  • Biohazard door sign
  • Biohazard labels
  • Biosafety cabinet
  • Tabletop centrifuge and microcentrifuge equipped with aerosol‐containment devices
  • 4°C refrigerator
  • −20° and −80°C freezers
  • Sink equipped with foot pedal
  • Cryogenic storage unit: mechanical −140°C freezer or liquid nitrogen cryogenic storage unit set up for vapor storage only
  • Cryogenic gloves
  • Personal protective equipment: Tyvek suits or surgical gowns (legs must be covered), shoe covers, face shields, disposable sleeve covers, gloves (non‐powdered latex and/or nitrile, with a long cuff)
  • Biohazard bags with temperature‐sensitive labels
  • Medical pathological waste (MPW) disposable containers for incineration
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

   Berger, E.A., Doms, R.W., Fenyo, E.M., Korber, B.T., Littman, D.R., Moore, J.P., Sattentau, Q.J., Schuitemaker, H., Sodroski, J., and Weiss, R.A. 1998. A new classification for HIV‐1. Nature 391:240.
   Berger, E.A., Murphy, P.M., and Farber, J.M. 1999. Chemokine receptors as HIV‐1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657‐700.
   Blankson, J.N., Persaud, D., and Siliciano, R.F. 2002. The challenge of viral reservoirs in HIV‐1 infection. Annu. Rev. Med. 53:557‐593.
   Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M., and Oldstone, M.B. 1994. Virus‐specific CD8+ cytotoxic T‐lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103‐6110.
   Brown, P.O. 1997. Integration. In Retroviruses (J.M. Coffin, S.H. Hughes, and H.E. Varmus, eds.) pp. 161‐203. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
   Centers for Disease Control and Prevention. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb. Mortal. Wkly. Rep. 41:1‐19.
   Centers for Disease Control and Prevention. 2001. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV and HIV and Recommendations for Postexposure Prophylaxis. MMWR 2001; 50(No.RR‐11):1‐67.
   Chun, T.W., Engel, D., Mizell, S.B., Hallahan, C.W., Fischette, M., Park, S., Davey, R.T., Jr., Dybul, M., Kovacs, J.A., Metcalf, J.A., Mican, J.M., Berrey, M.M., Corey, L., Lane, H.C., and Fauci, A.S. 1999. Effect of interleukin‐2 on the pool of latently infected, resting CD4+ T cells in HIV‐1‐infected patients receiving highly active anti‐retroviral therapy. Nat. Med. 5:651‐655.
   Fauci, A.S. 2003. HIV and AIDS: 20 years of science. Nat. Med. 7:839‐843.
   Freed, E.O. and Martin, M.A. 2001. HIVs and their replication. In Fields Virology, 4th ed. (D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, and S.E. Straus, eds.) pp. 1971‐2041. Lippincott Williams & Wilkins, Philadelphia.
   Gallo, R.C. 2002. Historical essay. The early years of HIV/AIDS. Science 298:1728‐1730.
   Gao, F., Bailes, E., Robertson, D.L., Chen, Y., Rodenburg, C.M., Michael, S.F., Cummins, L.B., Arthur, L.O., Peeters, M., Shaw, G.M., Sharp, P.M., and Hahn, B.H. 1999. Origin of HIV‐1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436‐441.
   Gottlieb, M.S., Schroff, R., Schanker, H.M., Weisman, J.D., Fan, P.T., Wolf, R.A., and Saxon, A. 1981. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305:1425‐1431.
   Heath, S.L., Tew, J.G., Tew, J.G., Szakal, A.K., and Burton, G.F. 1995. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377:740‐744.
   Hoffenbach, A., Langlade‐Demoyen, P., Dadaglio, G., Vilmer, E., Michel, F., Mayaud, C., Autran, B., and Plata, F. 1989. Unusually high frequencies of HIV‐specific cytotoxic T lymphocytes in humans. J. Immunol. 142:452‐462.
   Koup, R.A., Safrit, J.T., Cao, Y., Andrews, C.A., McLeod, G., Borkowsky, W., Farthing, C., and Ho, D.D. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650‐4655.
   Letvin, N.L. and Walker, B.D. 2003. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat. Med. 9:861‐866.
   McMichael, A.J. and Hanke, T. 2003. HIV vaccines 1983‐2003. Nat. Med. 9:874‐880.
   Mellors, J.W., Munoz, A., Giorgi, J.V., Margolick, J.B., Tassoni, C.J., Gupta, P., Kingsley, L.A., Todd, J.A., Saah, A.J., Detels, R., Phair, J.P., and Rinaldo, C.R. Jr. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV‐1 infection. Ann. Intern. Med. 126:946‐954.
   Ogg, G.S., Jin, X., Bonhoeffer, S., Dunbar, P.R., Nowak, M.A., Monard, S., Segal, J.P., Cao, Y., Rowland‐Jones, S.L., Cerundolo, V., Hurley, A., Markowitz, M., Ho, D.D., Nixon, D.F., and McMichael, A.J. 1998. Quantitation of HIV‐1‐specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103‐2106.
   Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., Orenstein, J.M., Kotler, D.P., and Fauci, A.S. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355‐358.
   Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., and Ho, D.D. 1996. HIV‐1 dynamics in vivo: Virion clearance rate, infected cell life‐span, and viral generation time. Science 271:1582‐1586.
   Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., and Ho, D.D. 1997. Decay characteristics of HIV‐1‐infected compartments during combination therapy. Nature 387:188‐191.
   Piatak, M. Jr., Saag, M.S., Yang, L.C., Clark, S.J., Kappes, J.C., Luk, K.C., Hahn, B.H., Shaw, G.M., and Lifson, J.D. 1993. High levels of HIV‐1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749‐1754.
   Pierson, T.C. and Doms, R.W. 2003. HIV‐1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 281:1‐27.
   Poli, G. and Fauci, A. 1995. Role of cytokines in the pathogenesis of human immunodeficiency virus infection. In Human Cytokines: Their Role in Disease and Therapy (B. Aggarwal, and R. Puri, eds.) pp. 421‐449. Blackwell Science, Cambridge, Mass.
   Pomerantz, R.J. and Horn, D.L. 2003. Twenty years of therapy for HIV‐1 infection. Nat. Med. 7:867‐873.
   Richman, D.D., Wrin, T., Little, S.J., and Petropoulos, C.J. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 100:4144‐4149.
   Sattar, S.A. and Springthorpe, V.S. 1991. Survival and disinfectant inactivation of the human immunodeficiency virus: A critical review. Rev. Infect. Dis. 13:430‐447.
   Steinman, R.M., Granelli‐Piperno, A., Pope, M., Trumpfheller, C., Ignatius, R., Arrode, G., Racz, P., and Tenner‐Racz, K. 2003. The interaction of immunodeficiency viruses with dendritic cells. Curr. Top. Microbiol. Immunol. 276:1‐30.
   Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar‐Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L., Nowak, M.A., Hahn, B.H., Kwong, P.D., and Shaw, G.M. 2003. Antibody neutralization and escape by HIV‐1. Nature 422:307‐312.
   Zhu, T., Mo, H., Wang, N., Nam, D.S., Cao, Y., Koup, R.A., and Ho, D.D. 1993. Genotypic and phenotypic characterization of HIV‐1 patients with primary infection. Science 261:1179‐1181.
Key References
   Biosafety in Microbiological and Biomedical Laboratories. US Department of Health and Human Services Publication No. (CDC) 93‐8395. US Government Printing Office, Washington, DC.
  Available online at http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm, these guidelines describe biosafety level 3 practices and summarizes the safety information on retroviruses.
   Centers for Disease Control and Prevention, 2001. See above.
  Available online at http://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf, this article contains the latest CDC guidelines for post‐exposure prophylaxis against HIV.
   Sattar and Springthorpe, 1991. See above.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library